Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A

Next Previous
Trial Profile

A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Turoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHFINDER 5
  • Sponsors Novo Nordisk

Most Recent Events

  • 01 Jan 2022 Results of post-hoc analysis of two studies (pathfinder 2 and pathfinder 5) assessing long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis, published in the Haemophilia.
  • 01 Sep 2020 End-of-trial safety and efficacy results of the combined main and extension phases published in the Journal of Thrombosis and Haemostasis
  • 09 Mar 2020 Results of NCT01731600 and NCT01480180 assesing plasma polyethylene glycol concentrations, repeatedly treated with N8-GP for periods of up to 5 years, published in the Drugs in R and D.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top